Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer

被引：3
|
作者：
Clark, Joseph I. [1 ,2 ]
Eisner, Robert M. [1 ]
Hofmeister, Craig [3 ]
Norton, John [1 ]
Thomas, Sachdev [1 ]
Choudhury, Abdul [2 ]
Petruzzelli, Guy [4 ]
Lathers, Deanne [5 ]
Young, M. Rita I. [5 ,6 ]
Lau, Ann [1 ]
Emami, Bahman [7 ]
机构：
[1] Loyola Univ, Med Ctr, Dept Med, Div Hematol Oncol,Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
[2] Jr Hines VA Hosp, Med Serv, Hines, IL USA
[3] Ohio State Univ, Dept Hematol, Columbus, OH 43210 USA
[4] Rush Univ, Med Ctr, Dept Otolaryngol, Chicago, IL 60612 USA
[5] Ralph H Johnson VA Med Ctr, Dept Otolaryngol, Res Serv, Charleston, SC USA
[6] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA
[7] Loyola Univ, Med Ctr, Dept Radiat Oncol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2009年 / 32卷 / 04期
关键词：
phase I; radiochemotherapy; docetaxel; high risk; head and neck cancer; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; ACTIVE-DRUG; CHEMOTHERAPY; FLUOROURACIL; CISPLATIN; INFUSION; TRIAL;
D O I：
10.1097/COC.0b013e31818da9c7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: This phase I study was designed to determine the maximum tolerated dose (MTD) and preliminary efficacy of docetaxel with concurrent radiotherapy (RT), in high-risk squamous cell carcinoma of the head and neck. Patients and Methods: Eligible patients had resected squamous cell carcinoma of the head and neck, histologically involved lymph nodes, and/or extranodal disease, and/or involved surgical margins and performance status 0 to 1. Treatment included weekly docetaxel with concurrent RT in a dose-finding study; a subsequent small cohort of patients was treated using the MTD of docetaxel. Results: Twenty patients were enrolled. Planned accrual was 25, but the study was closed prematurely because of slow accrual. The MTD was 15 mg/m(2). Dose-limiting toxicity was oral stomatitis. Therapy was well tolerated. Five patients experienced locoregional relapse at a median follow-up of 32 months. Conclusion: Docetaxel with concurrent RT has acceptable toxicity. This approach warrants further investigation in a phase II trial.
引用
收藏
页码：396 / 400
页数：5
相关论文
共 50 条
  • [21] Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience
    Mezi, Silvia
    Pomati, Giulia
    Botticelli, Andrea
    Roberto, Michela
    Cerbelli, Bruna
    Cirillo, Alessio
    Di Gioia, Cira
    Corsi, Alessandro
    Vullo, Francesco
    De Vincentiis, Marco
    Polimeni, Antonella
    Tombolini, Vincenzo
    Valentini, Valentino
    Marchetti, Paolo
    ANTI-CANCER DRUGS, 2020, 31 (10) : 1074 - 1083
  • [22] Concurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer. A phase I study
    Inohara, H
    Inoue, T
    Akahani, S
    Yamamoto, Y
    Takenaka, Y
    Nakagawa, T
    Isohashi, F
    Kubo, T
    ANTICANCER RESEARCH, 2004, 24 (06) : 4135 - 4140
  • [23] High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: Risk Factors for Recurrence and Impact of Adjuvant Treatment
    Trosman, Samuel J.
    Zhu, Angela
    Nicolli, Elizabeth A.
    Leibowitz, Jason M.
    Sargi, Zoukaa B.
    LARYNGOSCOPE, 2021, 131 (01) : E136 - E143
  • [24] Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer
    Suzuki, M
    Nishimura, Y
    Nakamatsu, K
    Kanamori, S
    Koike, R
    Kawamoto, M
    Mori, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (06) : 297 - 301
  • [25] HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors
    de Jong, Monique C.
    Pramana, Jimmy
    Knegjens, Joost L.
    Balm, Alfons J. M.
    van den Brekel, Michiel W. M.
    Hauptmann, Michael
    Begg, Adrian C.
    Rasch, Coen R. N.
    RADIOTHERAPY AND ONCOLOGY, 2010, 95 (03) : 365 - 370
  • [26] Postoperative Reduced Dose of Cisplatin Concomitant With Radiation Therapy in High-Risk Head and Neck Squamous Cell Carcinoma
    Franchin, Giovanni
    Minatel, Emilio
    Politi, Doriano
    Gobitti, Carlo
    Talamini, Renato
    Vaccher, Emanuela
    Savignano, Maria Gabriella
    Trovo, Marco
    Sulfaro, Sandro
    Barzan, Luigi
    CANCER, 2009, 115 (11) : 2464 - 2471
  • [27] Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer
    Allal, AS
    Zwahlen, D
    Becker, M
    Dulguerov, P
    Mach, N
    CANCER JOURNAL, 2006, 12 (01) : 63 - 68
  • [28] A phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients
    Willey, Christopher D.
    Murphy, Barbara A.
    Netterville, James L.
    Burkey, Brian B.
    Shyr, Yu
    Shakhtour, Bashar
    Kish, Bonnie
    Raben, David
    Chen, Changhu
    Song, John I.
    Kane, Madeleine A.
    Cmelak, Anthony J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (05): : 1323 - 1331
  • [29] Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study)
    Barnadas, Agusti
    Mesia, Ricard
    Majem, Margarita
    Galiana, Ramon
    Lopez-Pousa, Antonio
    de Vega, Jose M.
    Margeli, Mireia
    Valenti, Vicente
    Anglada, Lluis
    Lloansi, Ariadna
    Arellano, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (04) : 254 - 260
  • [30] Combined treatment with D-allose, docetaxel and radiation inhibits the tumor growth in an in vivo model of head and neck cancer
    Hoshikawa, Hiroshi
    Kamitori, Kazuyo
    Indo, Kanako
    Mori, Terushige
    Kamata, Mizuna
    Takahashi, Tomoko
    Tokuda, Masaaki
    ONCOLOGY LETTERS, 2018, 15 (03) : 3422 - 3428
12345